PMC3262388_01
Serum creatinine levels as a function of time (days).. Notes: Creatinine levels are marked with open red circles and the data points are connected with straight lines. For the purposes of reference, the normal creatinine range (0.5-1.3 mg/dL) is shown as open blue circles. The days corresponding to eculizumab administration are indicated by red asterisks along the horizontal time axis, appearing on days: 6, 13, 20, 27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 174, 188, and 202. The start and end dates of dialyses administration are marked on the time axis of the figure by two blue open triangles, on days 4 and 26.
cpaa-3-045f1.jpg
PMC3262388_01_cpaa-3-045f1.jpg
f1-cpaa-3-045
Figures 1-6 show treatment responses over time with respect to creatinine, C3, C4, LDH, haptoglobin, and platelets.
Lactate dehydrogenase as a function of time (days).. Notes: Lactate dehydrogenase levels are marked with open red circles and the data points are connected with straight lines. For the purposes of reference, the normal range (108-202 U/L) is shown as open blue circles. Lactate dehydrogenase is shown as a function of time (days). Lactate dehydrogenase gradually dropped after initiating treatment with eculizumab. Eculizumab administration is denoted by vertical tick marks (days 6, 13, 20, 27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 174, 188, and 202). The start and end dates of dialyses administration are marked on the time axis of the figure by two blue open triangles, on days 4 and 26. Four days after the first dose, lactate dehydrogenase dropped to 837 U/L. After the second dose of eculizumab on day 13, lactate dehydrogenase dropped to 556 U/L. A week after the third dose, lactate dehydrogenase was down to 349 U/L. Three days after the sixth dose, lactate dehydrogenase was normal. It did rise slightly before the seventh dose was due.
cpaa-3-045f2.jpg
PMC3262388_01_cpaa-3-045f2.jpg
f2-cpaa-3-045
Figures 1-6 show treatment responses over time with respect to creatinine, C3, C4, LDH, haptoglobin, and platelets.
Haptoglobin as a function of time (days).. Notes: Haptoglobin levels are marked with open red circles and the data points are connected with straight lines. For the purposes of reference, the normal range (62-197 mg/dL) is shown as open blue circles. Eculizumab administration is denoted by vertical tick marks (days 6, 13, 20, 27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 174, 188, and 202). Initial haptoglobin was <6 mg/dL (normal range 62-197 mg/dL). Five days after the third dose, haptoglobin was normal and remained normal until the time the seventh dose was due. Haptoglobin then dropped precipitously, indicating an ongoing need for the drug. Haptoglobin did increase again after the seventh dose on day 63, and later normalized to 71 mg/dL 3 days after receiving the eighth dose on day 69. The start and end dates of dialyses administration are marked on the time axis of the figure by two blue open triangles, on the days 4 and 26.
cpaa-3-045f3.jpg
PMC3262388_01_cpaa-3-045f3.jpg
f3-cpaa-3-045
Figures 1-6 show treatment responses over time with respect to creatinine, C3, C4, LDH, haptoglobin, and platelets.
C3 as a function of time (days).. Notes: C3 levels are marked with open red circles and the data points are connected with straight lines. For the purposes of reference, the normal range (83-184 mg/dL) is shown as open blue circles. C3 is shown as a function of time (days). Eculizumab administration is denoted by vertical tick marks (days 6, 13, 20, 27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 174, 188, and 202). The start and end dates of dialyses administration are marked on the time axis of the figure by two blue open triangles, on the days 4 and 26. After the second dose of eculizumab on day 13, C3 rose to 81. Thirteen days after the sixth dose, C3 was normal and remained normal.
cpaa-3-045f4.jpg
PMC3262388_01_cpaa-3-045f4.jpg
f4-cpaa-3-045
Figures 1-6 show treatment responses over time with respect to creatinine, C3, C4, LDH, haptoglobin, and platelets.
C4 as a function of time (days).. Notes: C4 levels are marked with open red circles and the data points are connected with straight lines. For the purposes of reference, the normal range (17 to 59 mg/dL) is shown as open blue circles. C4 is shown as a function of time (days). Eculizumab administration is denoted by vertical tick marks (days 6, 13, 20, 27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 174, 188, and 202). The start and end dates of dialyses administration are marked on the time axis of the figure by two blue open triangles, on days 4 and 26. The day after the second dose of eculizumab on day 13, C4 rose to 16. Three days after the sixth dose, C4 was normal and remained normal.
cpaa-3-045f5.jpg
PMC3262388_01_cpaa-3-045f5.jpg
f5-cpaa-3-045
Figures 1-6 show treatment responses over time with respect to creatinine, C3, C4, LDH, haptoglobin, and platelets.
Platelets as a function of time (days).. Notes: Platelet levels are marked with open red circles and the data points are connected with straight lines. For the purposes of reference, the normal range (150-450 x 109/L) is shown as open blue circles. The days corresponding to eculizumab administration are indicated by red asterisks along the horizontal time axis, appearing on days: 6, 13, 20, 27, 34, 48, 63, 70, 77, 84, 91, 98, 105, 112, 119, 133, 146, 160, 174, 188, and 202. On the day of transfer, hospital day 1, the patient underwent total abdominal colectomy. During surgery, she received 2U of pooled platelets. Initial platelets before surgery were 28 x 109/L. After surgery, her platelets rose, and continued to rise during the first 5 days of the admission, without additional transfusions. The rising platelets after colectomy suggested previous platelet consumption by a thrombotic microangiopathic process in the colon. After initiating eculizumab, her platelets continued to rise.
cpaa-3-045f6.jpg
PMC3262388_01_cpaa-3-045f6.jpg
f6-cpaa-3-045
Figures 1-6 show treatment responses over time with respect to creatinine, C3, C4, LDH, haptoglobin, and platelets.